JAGX's securities continue to be listed and traded on Nasdaq

KindlyMD is now providing nearly 80% statewide comprehensive insurance coverage

FDA Provides Positive Feedback to Company Regarding TH104 Phase 2 Program

Company Incorporating FDA Feedback into Phase 2 Protocol

Company Believes it is On-track to Initiate Phase 2 Trial

Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen product targeting at-home testing

Next-Gen Ainos Flora will advance with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kickoff

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older

Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older

Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis

Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral mucositis